Lucira Health (Lucira Health) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Lucira Health Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Lucira Health is: No Data: Cannot be evaluated.

Competitive Comparison of Lucira Health's Risk Assessment

For the Medical Devices subindustry, Lucira Health's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucira Health's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucira Health's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Lucira Health's Risk Assessment falls into.

Lucira Health (OTCPK:LHDXQ) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Lucira Health Risk Assessment Related Terms

Thank you for viewing the detailed overview of Lucira Health's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucira Health (Lucira Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucira Health Inc (OTCPK:LHDXQ) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

1412 62nd Street, Emeryville, CA, USA, 94608

Website

https://www.lucirahealth.com

Lucira Health Inc is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. It has developed a testing platform that produces high-complexity-laboratory-accurate molecular testing in a single-use and user-friendly test kit that is powered by two AA batteries and fit in the palm of a hand. The company's initial focus is within respiratory diseases, and initially for COVID-19 and influenza Types A and B indications.

Executives

Anthony Joseph Allen	officer: Chief Operations Officer	1412 62ND STREET, EMERYVILLE CA 94608
Epq Llc, Lcovd Safe Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Chad Boeding	other: CEO of 10% owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epiq Capital Group, Llc	10 percent owner	ONE LOMBARD STREET, SUITE 200, SAN FRANCISCO CA 94111
Epq Llc, Lcovd Ps	10 percent owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Lflu Ps	other: Less than 10% owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Epq Llc, Ltest Ps	other: Less than 10% Owner	9650 GATEWAY DRIVE, SUITE 200, RENO NV 89521
Richard Clavano Narido	officer: Interim CFO	12 HANSEN CT, MORAGA CA 94556
Ghazi Kashmolah	officer: Ex. VP &Chief Quality Officer	1412 62ND STREET, EMERYVILLE CA 94608
Kevin Walter Collins	officer: Chief Revenue Officer	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608
Dan George	officer: CFO and Treasurer	1412 62ND STREET, EMERYVILLE CA 94608
Erik T. Engelson	director, officer: President and Chief Executive	1412 62ND STREET, EMERYVILLE CA 94608
Debkishore Mitra	director, officer: Chief Technology Officer	1412 62ND STREET, EMERYVILLE CA 94608
Tamanna Prashar	officer: Vice President	1412 62ND STREET, EMERYVILLE CA 94608
Alison Mccauley	director	C/O LUCIRA HEALTH, INC., 1412 62ND STREET, EMERYVILLE CA 94608